---
title: "T&K: CKBA cream for rosacea indications to conduct seamless Phase II/III adaptive clinical trials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/258839813.md"
description: "According to the Zhitong Finance APP, T&K announced that its holding subsidiary Jiangsu Bochuangyuan Biomedical Technology Co., Ltd. (referred to as \"Bochuangyuan\") has received the \"Drug Clinical Trial Approval Notice\" issued by the National Medical Products Administration, agreeing to conduct a seamless adaptive clinical trial for CKBA cream for the indication of rosacea in Phase II/III"
datetime: "2025-09-25T09:17:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/258839813.md)
  - [en](https://longbridge.com/en/news/258839813.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/258839813.md)
generator: "portal-rs"
---

# T&K: CKBA cream for rosacea indications to conduct seamless Phase II/III adaptive clinical trials

According to the Zhitong Finance APP, T&K (301263.SZ) announced that its holding subsidiary Jiangsu Bochuangyuan Biomedical Technology Co., Ltd. (referred to as "Bochuangyuan") has received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration, agreeing to conduct a seamless adaptive clinical trial for the CKBA cream for the indication of rosacea in Phase II/III

### Related Stocks

- [301263.CN](https://longbridge.com/en/quote/301263.CN.md)

## Related News & Research

- [US health agencies report 55 cases of E. coli and salmonella infections tied to alfalfa sprouts](https://longbridge.com/en/news/296645342.md)
- [UNM and ScienceSoft Launch First Statewide WHO Healthy Aging Initiative in US](https://longbridge.com/en/news/296641162.md)
- [CDC lifts beneficial stake in Exosens to 11.71% of capital, 13.87% of voting rights](https://longbridge.com/en/news/296499698.md)
- [Frozen blueberries recall categorized under FDA's highest Class I risk level](https://longbridge.com/en/news/296506599.md)
- [13:49 ETVascarta Outlines Proposed Mechanistic Link Between VAS-101's (Vasceptor®) Vascular and Red Blood Cell Effects in Sickle Cell Disease](https://longbridge.com/en/news/296524035.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**